The proceeds of the capital round are considerably higher than Argenx itself had previously indicated. The company announced on Monday that it wanted to raise $750 million. Investors, mainly in the United States and Europe, subscribed to more than 2 million shares, at a price that was fractionally lower than the record price of the share on Monday when the stock market closed.
The share of the biotech company shot up 31 percent on Monday on the Brussels stock exchange, to 437.60 euros, after the announcement of positive results for a new treatment. On Tuesday, the stock was suspended pending news about the capital round. That followed Wednesday morning, after which trading in the share could resume at 9 a.m. Around 9.10 am, the Argenx share was quoted with a profit of more than 3.5 percent, above 450 euros.